JP2017518071A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017518071A5 JP2017518071A5 JP2017508762A JP2017508762A JP2017518071A5 JP 2017518071 A5 JP2017518071 A5 JP 2017518071A5 JP 2017508762 A JP2017508762 A JP 2017508762A JP 2017508762 A JP2017508762 A JP 2017508762A JP 2017518071 A5 JP2017518071 A5 JP 2017518071A5
- Authority
- JP
- Japan
- Prior art keywords
- chain
- chimeric antigen
- antigen receptor
- seq
- specific multi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461987805P | 2014-05-02 | 2014-05-02 | |
| US61/987,805 | 2014-05-02 | ||
| PCT/EP2015/059523 WO2015166056A1 (en) | 2014-05-02 | 2015-04-30 | Cs1 specific multi-chain chimeric antigen receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017518071A JP2017518071A (ja) | 2017-07-06 |
| JP2017518071A5 true JP2017518071A5 (enExample) | 2018-06-14 |
Family
ID=53052850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017508762A Pending JP2017518071A (ja) | 2014-05-02 | 2015-04-30 | Ｃｓ１特異的多重鎖キメラ抗原受容体 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20170051037A1 (enExample) |
| EP (2) | EP3137498A1 (enExample) |
| JP (1) | JP2017518071A (enExample) |
| AU (1) | AU2015254595B2 (enExample) |
| WO (1) | WO2015166056A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6839074B2 (ja) | 2014-09-17 | 2021-03-03 | ノバルティス アーゲー | 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング |
| CN114085856A (zh) * | 2014-12-05 | 2022-02-25 | 希望之城公司 | Cs1靶向性嵌合抗原受体修饰的t细胞 |
| CA2976089C (en) | 2015-02-10 | 2026-01-13 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies |
| IL303972A (en) | 2015-04-08 | 2023-08-01 | Novartis Ag | CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell |
| GB201519900D0 (en) * | 2015-11-11 | 2015-12-23 | Ucl Business Plc | Chimeric antigen receptor |
| WO2017192536A1 (en) | 2016-05-02 | 2017-11-09 | University Of Kansas | Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy |
| WO2020009868A1 (en) * | 2018-07-03 | 2020-01-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-slamf7 chimeric antigen receptors |
| CN114650829A (zh) * | 2019-09-05 | 2022-06-21 | 索伦托药业有限公司 | 结合bcma的二聚体抗原受体(dar) |
| CN111234033B (zh) * | 2020-01-21 | 2021-05-11 | 南京北恒生物科技有限公司 | 多链嵌合抗原受体及其用途 |
| EP4168438A4 (en) * | 2020-06-22 | 2024-07-10 | Ramot at Tel-Aviv University Ltd. | Multi subunit protein modules, cells expressing same and uses thereof |
| CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
| CN114907485B (zh) * | 2021-02-08 | 2024-04-26 | 浙江大学 | 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体 |
| CN116410331B (zh) * | 2021-12-31 | 2024-01-30 | 合源生物科技(天津)有限公司 | 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用 |
| CN116949099B (zh) * | 2023-07-12 | 2024-04-02 | 山东大学第二医院 | 一种靶向cd38和cs1抗原的并联嵌合抗原受体t细胞及其制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| AU4328801A (en) | 2000-02-24 | 2001-09-03 | Xcyte Therapies Inc | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| EP1620537B1 (en) | 2003-03-14 | 2012-10-24 | Cellectis SA | Large volume ex vivo electroporation method |
| US20050025763A1 (en) * | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| JP4758984B2 (ja) * | 2004-03-29 | 2011-08-31 | アボット バイオセラピューティクス コーポレイション | 抗ｃｓ１抗体の治療的使用 |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| SG10201806573TA (en) | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| AU2013312838B2 (en) * | 2012-09-04 | 2018-11-29 | Cellectis | Multi-chain chimeric antigen receptor and uses thereof |
-
2015
- 2015-04-30 EP EP15720694.7A patent/EP3137498A1/en not_active Withdrawn
- 2015-04-30 EP EP19159653.5A patent/EP3524616A1/en active Pending
- 2015-04-30 US US15/308,047 patent/US20170051037A1/en not_active Abandoned
- 2015-04-30 AU AU2015254595A patent/AU2015254595B2/en active Active
- 2015-04-30 JP JP2017508762A patent/JP2017518071A/ja active Pending
- 2015-04-30 WO PCT/EP2015/059523 patent/WO2015166056A1/en not_active Ceased
-
2019
- 2019-03-26 US US16/365,367 patent/US20190359680A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017518071A5 (enExample) | ||
| JP2017519502A5 (enExample) | ||
| JP2017522893A5 (enExample) | ||
| JP2021087455A5 (enExample) | ||
| JP2020114264A5 (enExample) | ||
| JP2020511136A5 (enExample) | ||
| JP2022113880A5 (enExample) | ||
| JP2017524367A5 (enExample) | ||
| JP2021094037A5 (enExample) | ||
| JP2019527557A5 (enExample) | ||
| FI4324851T3 (fi) | BCMA-spesifisiä kimeerisiä antigeenireseptoreita ja niiden käyttöjä | |
| JP2020513754A5 (enExample) | ||
| JP2018508219A5 (enExample) | ||
| JP2025065142A5 (enExample) | ||
| HRP20241057T1 (hr) | Kimerni antigenski receptori na osnovu jedno-domenskih antitijela i načini njihove uporabe | |
| JP2020517295A5 (enExample) | ||
| JP2019527537A5 (enExample) | ||
| JP2016514462A5 (enExample) | ||
| JP2019523301A5 (enExample) | ||
| JP2017513478A5 (enExample) | ||
| JP2020513829A5 (enExample) | ||
| JP2017537925A5 (enExample) | ||
| IL264144B1 (en) | Antibody 18a2 against claudin and its use | |
| JP2021500881A5 (enExample) | ||
| HRP20211978T1 (hr) | Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe |